Concise drug review: azacitidine and decitabine.

The introduction of the hypomethylating agents azacitidine and decitabine has been a major advancement in the treatment of patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are ineligible for more intensive treatments. This concise drug review summarizes the current state of treatment with azacitidine and decitabine.

[1]  M. Carducci,et al.  Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  H. Kantarjian,et al.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.

[3]  J. Issa,et al.  Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine , 2008, Leukemia & lymphoma.

[4]  M. Beran.  Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. , 2000, International journal of hematology.

[5]  G. Mufti,et al.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes , 2011, Cancer.

[6]  M. Lübbert,et al.  Superiority of prolonged low‐dose azanucleoside administration? , 2006, Cancer.

[7]  J. Pirkle,et al.  The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. , 1976, Cancer research.

[8]  G. Marcucci,et al.  Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes , 2005, Journal of clinical pharmacology.

[9]  M. T. McCabe,et al.  Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications , 2009, Clinical Cancer Research.

[10]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[11]  M. T. McCabe,et al.  Cancer DNAMethylation : Molecular Mechanisms and Clinical Implications , 2009 .

[12]  P. Fenaux,et al.  Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents , 2012, Leukemia & lymphoma.

[13]  A. Stamatoullas,et al.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. , 2011, Blood.

[14]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[15]  J. Issa,et al.  Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome , 2007, Cancer.

[16]  B. Esterni,et al.  Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure , 2012, British journal of haematology.

[17]  P. Fenaux,et al.  Optimizing hypomethylating agents in myelodysplastic syndromes , 2012, Current opinion in hematology.

[18]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[19]  J. Maciejewski,et al.  Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. , 2012, Blood.

[20]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Mufti,et al.  Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine * , 2010, European journal of haematology.

[23]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Stambaugh,et al.  Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. , 1972, Cancer chemotherapy reports.

[25]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[26]  S. Guichard,et al.  Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[27]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Issa,et al.  Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. , 2010, Clinical lymphoma, myeloma & leukemia.

[29]  In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine , 2010, Cancer Chemotherapy and Pharmacology.

[30]  J. Issa,et al.  Targeting DNA Methylation , 2009, Clinical Cancer Research.

[31]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[32]  M. Mancini,et al.  Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response , 2012, Leukemia & lymphoma.

[33]  J. Issa,et al.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.

[34]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[37]  J. Issa.  Epigenetic changes in the myelodysplastic syndrome. , 2010, Hematology/oncology clinics of North America.

[38]  E. Vellenga,et al.  Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme , 2011, British journal of haematology.

[39]  J. Dipersio,et al.  Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) , 2008, Cancer Chemotherapy and Pharmacology.